对布劳恩关于“ASAS-EULAR 轴性脊柱关节炎管理建议：2022 年更新”的通信的回复 - Suppr

Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun .

作者信息

Ramiro Sofia, Nikiphorou Elena, Sepriano Alexandre, Ortolan Augusta, Webers Casper, Baraliakos Xenofon, Landewé Robert Bm, van der Heijde Désirée

机构信息

Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands.

出版信息

Ann Rheum Dis. 2023 Sep;82(9):e206. doi: 10.1136/ard-2023-223937. Epub 2023 Mar 6.

DOI:10.1136/ard-2023-223937

PMID:36878690

Abstract

摘要

相似文献

Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun .对布劳恩关于“ASAS-EULAR 轴性脊柱关节炎管理建议：2022 年更新”的通信的回复

Ann Rheum Dis. 2023 Sep;82(9):e206. doi: 10.1136/ard-2023-223937. Epub 2023 Mar 6.

Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".关于“ASAS-EULAR 轴性脊柱关节炎管理建议：2022 年更新”的通信

Ann Rheum Dis. 2023 Sep;82(9):e205. doi: 10.1136/ard-2023-223935. Epub 2023 Feb 3.

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.生物改善病情抗风湿药的疗效与安全性：一项系统性文献综述，为2022年更新的ASAS-EULAR轴性脊柱关节炎管理推荐提供依据

Ann Rheum Dis. 2023 Jan;82(1):130-141. doi: 10.1136/ard-2022-223298. Epub 2022 Oct 21.

Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto .关于莫尔托所著《严格控制和达标治疗策略在轴性脊柱关节炎中的疗效：开放标签、实用性、整群随机TICOSPA试验结果》的通信

Ann Rheum Dis. 2023 Dec;82(12):e229. doi: 10.1136/annrheumdis-2021-221423. Epub 2021 Nov 1.

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question.2023 年，中轴型脊柱关节炎是否需要逐渐减少生物靶向改善病情抗风湿药物：这是一个问题。

Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101869. doi: 10.1016/j.berh.2023.101869. Epub 2023 Aug 30.

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.非药物和非生物干预措施的疗效与安全性：一项系统文献综述，为2022年更新的ASAS/EULAR轴性脊柱关节炎管理推荐提供依据

Ann Rheum Dis. 2023 Jan;82(1):142-152. doi: 10.1136/ard-2022-223297. Epub 2022 Oct 19.

Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings).《SPARTAN 二十年：从创立到影响（SPARTAN 2023 年会论文集）》。

Curr Rheumatol Rep. 2024 Mar;26(3):96-101. doi: 10.1007/s11926-023-01131-8. Epub 2024 Jan 12.

Response to: Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physicianreported spondylitis'?' by Siebert and Marzo-Ortega.对西伯特和马佐-奥尔特加所著《关于“随机对照试验中抗白细胞介素-23疗法对轴性脊柱关节炎无效，但在银屑病关节炎相关‘医生报告的脊柱炎’的事后分析中有效？”的通信》的回复

Ann Rheum Dis. 2023 Aug;82(8):e186. doi: 10.1136/annrheumdis-2021-221816. Epub 2021 Nov 29.

Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.关于“抗IL-23疗法在随机对照试验中对轴性脊柱关节炎无效，但在银屑病关节炎相关‘医生报告的脊柱炎’的事后分析中有效？”的通信

Ann Rheum Dis. 2023 Aug;82(8):e185. doi: 10.1136/annrheumdis-2021-221799. Epub 2021 Nov 29.

Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli by Huang .对米凯罗利（Micheroli）的《关于“瑞士临床质量管理队列中，既往使用过肿瘤坏死因子抑制剂的中轴型脊柱关节炎患者中，司库奇尤单抗与另一种肿瘤坏死因子抑制剂的疗效对比”的通信》的回复作者：黄

Ann Rheum Dis. 2022 Nov;81(11):e227. doi: 10.1136/annrheumdis-2020-218832. Epub 2020 Sep 15.

引用本文的文献

Sacroiliac damage on MRI in axial spondyloarthritis and chronic back pain, women with postpartum back pain, runners and healthy subjects.轴向型脊柱关节炎、慢性背痛、产后背痛女性、跑步者及健康受试者的骶髂关节MRI损伤情况

RMD Open. 2025 May 28;11(2):e005555. doi: 10.1136/rmdopen-2025-005555.

Global research trends in biological therapy for ankylosing spondylitis: A comprehensive visualization and bibliometric study (2004-2023).强直性脊柱炎生物治疗的全球研究趋势：一项全面的可视化和文献计量学研究（2004 - 2023年）

Hum Vaccin Immunother. 2025 Dec;21(1):2445900. doi: 10.1080/21645515.2024.2445900. Epub 2025 Jan 15.

Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS).疑似或已知中轴型脊柱关节炎影像学转诊的临床信息：来自脊柱关节炎评估协会（ASAS）的建议。

Ann Rheum Dis. 2024 Nov 14;83(12):1636-1643. doi: 10.1136/ard-2024-226280.

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.接受托法替尼治疗的强直性脊柱炎患者的疼痛、晨僵、疲劳和疾病活动改善时间：一项事后分析。

Arthritis Res Ther. 2024 May 24;26(1):105. doi: 10.1186/s13075-024-03313-w.

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.比较比美克单抗在中轴型脊柱关节炎中的疗效和安全性：系统文献回顾和网络荟萃分析。

Rheumatology (Oxford). 2024 May 2;63(5):1195-1205. doi: 10.1093/rheumatology/kead598.

Comparison of biologics and small-molecule drugs in axial spondyloarthritis: a systematic review and network meta-analysis.生物制剂与小分子药物在轴性脊柱关节炎中的比较：一项系统评价和网状荟萃分析

Front Pharmacol. 2023 Oct 24;14:1226528. doi: 10.3389/fphar.2023.1226528. eCollection 2023.

JAK Inhibitors for the Treatment of Axial Spondyloarthritis.用于治疗中轴型脊柱关节炎的JAK抑制剂

Mediterr J Rheumatol. 2023 Jun 30;34(2):129-138. doi: 10.31138/mjr.34.2.129. eCollection 2023 Jun.

Disease activity indexes might not capture the same disease aspects in males and females with ankylosing spondylitis: A real-world nationwide analysis.疾病活动指数可能无法反映强直性脊柱炎男性和女性患者相同的疾病情况：一项全国性真实世界分析。

Front Med (Lausanne). 2022 Dec 21;9:1078325. doi: 10.3389/fmed.2022.1078325. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun .

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献